The purpose of this study is to determine the side-effects and effectiveness of a new type of chemoradiotherapy treatment for patients who have had surgery for stomach cancer. The treatment uses epirubicin, cisplatin, and 5-fluorouracil (ECF) chemotherapy together with radiotherapy.

Official Title


Gastric Cancer

Study Type


Study Design

Treatment, Non-Randomized, Open Label, Historical Control, Single Group Assignment, Safety/Efficacy Study

Further Details

Primary Outcomes: The percentage of patients who develop grade 3 or grade 4 haematological and gastrointestinal acute toxicity; The percentage of patients who complete the planned chemoradiation protocol; The percentage of major radiotherapy protocol violationsSecondary Outcomes: Median survival and overall survival at 3 yearsExpected Total Enrollment: 52

Study Start

Study start: June 2003; Expected completion: December 2008

Eligibility & Criteria

Inclusion Criteria:All of the following must apply:Histologically proven adenocarcinoma of the stomach or gastro-oesophageal junction that is:Completely resected with negative margins Stage T3,4 and/or N1,2 patients who have undergone a D2 nodal dissection can be entered on the study at the discretion of the treating clinician. – Age greater than or equal to 18 years – Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, 2 Adequate organ function defined as follows: *Bone marrow: Haemoglobin greater than or equal to 90 g/L; Neutrophil count greater than or equal to 1.5 x 10^9 /L; Platelet count greater than or equal to 100 x 10^9 /L *Hepatic: Serum bilirubin less than or equal to 1.5 x ULN; AST and/or ALT less than or equal to 3.0 x ULN; *Renal: Serum creatinine less than or equal to 0.150 mmol/L, and calculated creatinine clearance greater than or equal to 50mL/min. – Adequate oral nutrition (intake greater than or equal to 1500 calories/day). This is to be assessed by a dietician prior to commencing treatment. – Disease which can be radically treated to 45 Gy with standard fractionation. – Patient able to be treated with infusional 5-fluorouracil (5-FU) and ECF chemotherapy. – Written informed consent Exclusion Criteria:None of the following must apply:- Evidence of metastatic disease. – Prior chemotherapy or radiotherapy – Patients with other significant underlying medical conditions that may be aggravated by the study treatment or are not controlled. – Pregnant or lactating females or female patients of childbearing potential who have not been surgically sterilized or are without adequate contraceptive measures. Cardiac failure (relevant to the use of epirubicin):- Patients with myocardial infarction within the last 6 months; – Patients with New York Heart Association class III/IV congestive heart failure

Total Enrolment

Contact Details

Australia, New South Wales Westmead Hospital, Sydney, New South Wales, 2145, Australia; Recruiting Jayasingham Jayamoham, MD +61 2 98456499 Jayasingham Jayamoham, Principal Investigator Newcastle Mater Misericordiae Hospital, Newcastle, New South Wales, 2298, Australia; Recruiting Chris Wratten, MD +61 (0) 2 4921 1475 Chris Wratten, Principal Investigator Royal Prince Alfred Hospital, Sydney, New South Wales, 2050, Australia; Recruiting George Hruby, MD +61 (0) 2 95158057 George Hruby, Principal Investigator Royal North Shore Hospital, Sydney, New South Wales, 2069, Australia; Recruiting Graeme Morgan, MD +61 2 99265009 Graeme Morgan, Principal InvestigatorAustralia, Queensland Princess Alexandra Hospital, Brisbane, Queensland, 4102, Australia; Recruiting Jennifer Harvey, MD +61 (0)7 32406798 Jennifer Harvey, Principal InvestigatorAustralia, Victoria Peter MacCallum Cancer Centre, Melbourne, Victoria, 8006, Australia; Recruiting Trevor Leong, MD +61 3 96561111 Trevor Leong, Principal Investigator Austin Health, Melbourne, Victoria, 3081, Australia; Recruiting Daryl Lim Joon, MD + 61 (0) 3 9496 2800 Daryl Lim Joon, Principal InvestigatorAustralia, Western Australia Sir Charles Gairdner Hospital, Perth, Western Australia, 6009, Australia; Recruiting Nigel Spry, MD +61 (0) 8 93464900 Nigel Spry, Principal Investigator

All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.